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Abstract
Introduction: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) hampers the targets of
rheumatoid arthritis (RA) treatment, obtaining low disease activity and decreasing radiological progression. This
study investigates if, and to what extent, non-adherence to treatment would lead to a higher 28-joint count disease
activity score (DAS28) in the first year after diagnosis.
Methods: Adult patients from an ongoing cohort study on treatment adherence were selected if they fulfilled the
EULAR/ACR2010 criteria for RA, and were to start with their first DMARDs. Clinical variables were assessed at
baseline and every 3 months. Non-adherence was continuously electronically measured and was defined as the
proportion of days with a negative difference between expected and observed openings of the medication
container out of the 3-month period before DAS28 measurement. Generalized linear mixed models were used to
investigate whether the DAS28 related to non-adherence. Covariates included were age, sex, baseline DAS28,
rheumatoid factor positivity, anti-cyclic citrullinated peptide antibodies (ACPA) positivity, anxiety, depression, weeks
of treatment, number of DMARDs used, education level, use of subcutaneous methotrexate and biological use.
Results: One hundred and twenty patients met the inclusion criteria for RA. During the study period 17 patients
became lost to follow-up. There was a decline in adherence over time for all DMARDs except for prednisone.
Non-adherence is a predictor of disease activity in the first 6 months of therapy, adjusted for weeks of treatment,
baseline DAS28, and baseline anxiety.
Conclusions: Non-adherence relates to disease activity. Therefore, interventions towards enhancing adherence can
improve disease outcome.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease, which is characterized by joint inflammation with
pain, swelling, damage and disability [1]. Early and ad-
equate treatment with disease-modifying antirheumatic
drugs (DMARDs) will prevent the disease from becoming
worse. According to the guidelines, rheumatologists
should strive for remission, or at least low disease activity
within 3 months, in order to obtain the best functional
and radiological outcomes [2, 3].
Adherence to DMARD therapy is important to reach
the desired treatment outcome as stated in the guide-
lines, especially at the start of treatment. Following the
guidelines for the treatment of RA, drug therapy should
be adjusted at least every 3 months until the desired
treatment target is reached [1, 3]. When patients are
non-adherent to their drug therapy, it seems as if treat-
ment fails, whereas in fact patients are not taking their
medication. When treatment with synthetic DMARDs fails
due to overlooked non-adherence, a step-up in therapy will
be made. The first step-up is treatment with higher
DMARD dosages or adding other synthetic DMARDs, and
adds unnecessary risks to the treatment. When this step-up
also fails, treatment with biological, and more expensive,
DMARDs will be considered, adding even more costs and
risks [3]. When prognostic unfavorable factors are present,
an even earlier switch to biological DMARDs can be made
according to the guidelines [3].
At the individual level, large differences in treat-
ment response, as measured with the 28-joint count
disease activity score (DAS28), are observed [4]. It is
unclear which factors attribute to these differences.
Studies have shown that amongst many factors, part
of them are explained by age, sex, baseline DAS28
score, presence of rheumatoid factor (RF) or anti-
cyclic citrullinated peptide antibodies (ACPA), type of
treatment given, anxiety, coping with pain and locus
of control (the extent to which patients believe they
can control the pain) (Xiong H, Kuijper TM, de Jong
PHP, Weel AEAM, Gerards AH, van Zeben J, et al.:
Higher levels of baseline anxiety is a predictor of dis-
ease activity at three months in early arthritis patients
initiating therapy with DMARDs, submitted) [5–10].
Non-adherence would also be a logical contributor to
individual differences in DAS28.
Early and adequate treatment of RA will prevent the
disease from becoming worse, and therefore adherence
to the treatment is important for the management of
RA. The consequences of non-adherence will not only
affect the patient’s disease activity, but also the rheumatolo-
gist’s treatment decisions [11–13], which may lead to higher
health care costs. Adherence in this early phase of disease
has not been explored before. Furthermore, the extent to
which non-adherence contributes to higher DAS28 in the
first year of treatment is not yet determined. This study
investigates if, and to what extent, non-adherence to
DMARDs would lead to higher DAS28 scores in the first
year after diagnosis.
Methods
Patients
A sample of 300 patients was consecutively recruited in
11 regional hospitals in the southwest of the Netherlands
from January 2012 to July 2014 for a cohort study on
DMARD adherence. Patients who were willing to partici-
pate were followed up for 1 year. Patients were included if
they were at least 18 years old, were started on one or
more DMARDs for RA for the first time, and were able to
sufficiently read and understand the Dutch language. For
the present analysis, we only selected those patients in-
cluded before January 2014 and who were diagnosed with
RA according to the European League Against Rheuma-
tism (EULAR)/American College of Rheumatology (ACR)
2010 criteria for RA.
Participants in the study were, on a fixed time interval,
seen by a research nurse or specialized rheumatology
nurse after their regular rheumatologist consultation. Be-
cause the time interval in which the patient is seen by
the rheumatologist differed per hospital, the time inter-
vals vary. In the first year after diagnosis, RA patients
are mostly seen every 3 months, but this time interval
varied depending on the rheumatologist follow-up
appointment.
The Erasmus MC medical research ethics committee
gave their approval to perform the study. Each hospital’s
board of directors gave their approval for participation
in the study. All participants gave written informed con-
sent for their participation and for retrieving relevant
clinical data from their patient file.
Primary outcome
Every 3 months, the DAS28 was measured by a trained
rheumatology nurse. The score comprises four domains:
swollen joint count (SJC), tender joint count (TJC),
erythrocyte sedimentation rate (ESR) and a patient gen-
eral health assessment using a visual analogue scale
(VAS). For patients who dropped out of the study, but
did not withdraw their consent, the DAS28 score was
retrieved from the patient files.
Clinical covariates
Clinical variables assessed at baseline included symptom
duration before diagnosis, ACPA, RF, ESR (or C-reactive
protein (CRP)) and joint involvement. ACPA and RF
were combined for a RF/ACPA positivity score. Symp-
tom duration was dichotomized in more or less than
6 weeks, according to the EULAR/ACR 2010 criteria for
RA. The number of DMARDs used was counted and
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analyzed as a continuous measure. The use of either
subcutaneous methotrexate (MTX) or biologicals was
noted from the patient file and entered as a binary
variable.
Psychosocial covariates
Symptoms of anxiety and depression were measured at
baseline with the Hospital Anxiety and Depression Scale
(HADS) [14]. The questionnaire has two subscales: one
for anxiety and one for depression. The scores range be-
tween 0 and 21, higher scores indicating more symptoms
of anxiety or depression.
Adherence measurement
Non-adherence was measured per DMARD using a
‘medication event monitoring system’ (MEMS) device,
which consists of a medication vial and a MEMS cap.
The MEMS uses a microprocessor in the medication
container cap to record day and time of each vial open-
ing. The data stored in the MEMS cap is transferred into
a web-based data platform, which compiles hour-by-
hour drug dosing histories, and in which medication
regimen changes are noted. Indirect adherence measure-
ment with MEMS is regarded as a gold standard, since it
objectively measures a necessary behavioural step for ad-
herence in ‘real time’ over a continuum. Disadvantages
of using MEMS are the high price, the fact that it does
not prove ingestion of medication and that it might be
seen as an intervention, although this intervention effect
is regarded as negligible [15]. Nursing and medical staff
were blind to the adherence data throughout the study.
Extra openings of the MEMS cap were ignored, be-
cause these mostly do not represent medication intake,
but openings by pharmacists. These would otherwise
lead to an overestimation of adherence.
When patients stopped using one or more DMARD
on the rheumatologist’s advice, for example in case of
laboratory abnormalities, this was noted as a non-
monitored period, which means that this period was not
assigned as a non-adherence event.
For each individual patient and per DMARD, we
calculated per day if there was medication underuse.
Underuse was defined as a negative difference between
the amount of observed openings minus the amount of
expected openings. For MTX, we calculated the under-
use not per day, but per week, since this medicine only
needs to be ingested weekly. For the 12-week period be-
fore each DAS28 measurement, we calculated the pro-
portion of days of DMARD underuse. If a patient used
multiple DMARDs in the 12-week period, the mean
underuse proportion was calculated. Adherence was also
dichotomized using a non-adherence proportion above
0.2 (80 % or less adherence) and using a non-adherence
proportion above 0.1 (90 % or less adherence).
When a patient used subcutaneous MTX, the patient
was asked to put their folic acid in the MEMS container.
The openings of the medication cap to take folic acid
would then represent the use of subcutaneous MTX. Ad-
herence to biologicals could not be measured. Patients
that used biologicals also used other synthetic DMARDs
to which adherence could be measured.
Statistical analysis
Characteristics of the study population and non-
adherence per DMARD were described with means,
standard deviations, medians, interquartile ranges and
percentages as appropriate. Four regression models were
run with DAS28 as dependent continuous outcome; at
T1, over the period T1 to T2 (two time points), the period
T1 to T3 (three time points), and the period T1 to T4
(four time points) respectively.
First, univariate linear regression was performed for
the T1 model to identify eligible predictors for the
DAS28 score at T1. Predictors entered in the univariate
regression were: standardized age, sex, baseline DAS28,
RF/ACPA positivity, baseline anxiety, baseline depression,
number of weeks using DMARDs, education level (low,
medium or high), non-adherence, number of DMARDs
used, use of subcutaneous MTX and biological use. Non-
adherence and covariates with a p value lower than 0.2
were entered in the multivariate model.
For the influence of non-adherence on DAS28 over T1
to T2 (two time points), T1 to T3 (three time points) and
T1 to T4 (four time points), multilevel regression models
were performed with patients in the upper level and their
repeated measures in the lower level. Variables that were
taken into account in the models to predict DAS28 over
time were: standardized age, sex, baseline DAS28, RF/
ACPA positivity, baseline anxiety, baseline depression,
number of weeks using DMARDs, education level (low,
medium or high), non-adherence, number of DMARDs
used, use of subcutaneous MTX and biological use. All
possible predictors were entered in a univariate multilevel
regression, taking into account the evolution of disease ac-
tivity over time. Non-adherence and covariates with a p
value lower than 0.2 were entered in the multilevel model.
Because of potential collinearity between anxiety and de-
pression, only one of these covariates will be included in
the multivariate models.
If our study was a hypothesis-testing study, a Bonferroni
correction should have been applied because of the
number of possible covariates in the analysis. However,
because of the explorative character of our study this
requirement would be too strict, since then we would
need a p value below 0.004 to reach statistical significance,
and then no covariates would be left over.
A p value below 0.05 was considered statistically
significant.
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Results
Participants
Before January 2014, 275 patients were asked to partici-
pate. Of those, 71 patients declined to participate and
three were excluded. The EULAR/ACR 2010 criteria for
RA were fulfilled by 120 of the 201 participants. During
the study period, 17 patients became lost to follow-up
(Fig. 1). Reasons for dropping out varied. Two patients
stopped because of serious comorbidities, four patients
did not show up at the study visits. Table 1 depicts the
baseline variables. There are no significant differences
between patients who became lost to follow-up and
patients with complete follow-up.
T1 (3 months) ranged from 5 to 20 weeks (mean
12 weeks), T2 (6 months) ranged from 16 to 33 weeks
(mean 26 weeks), T3 (9 months) ranged from 20 to
49 weeks (mean 38 weeks) and T4 ranged from 41 to
68 weeks (mean 52 weeks). The distribution of weeks
per time point was normal.
Disease activity
The mean DAS28 changed over time from 4.7 to 3.7
(3 months) to 2.7 (6 months), and 2.5 (9 and 12 months).
For patients who became lost to follow-up during the
cohort, the mean DAS28 improved more in the first
3 months of treatment (from 4.6 to 2.5), but worsened
slightly after 9 months (from 2.5 to 3.0). Figure 2 depicts
the course of the DAS28 over time for adherent (underuse
proportion less than 0.1) and non-adherent (underuse
proportion more than 0.1) patients. Non-adherent pa-
tients have a higher DAS28 (p = 0.01), especially at T2
(3 months). The proportion of patients achieving remis-
sion (DAS28 < 2.6) is at baseline 5, 41.4% at T2, 58.3 % at
T3, 61.2 % at T4, and 57.9 % at T5. When we split the
patients up into adherent and non-adherent, two times
more adherent patients are in remission (Fig. 2) (p <0.05),
especially at T2 (3 months of treatment).
Non-adherence
Most patients were started on monotherapy, of which
MTX was prescribed the most often (43.3 %). A combin-
ation of MTX and prednisone bridging therapy with or
without an additional DMARD was started for 32.5 % of
the patients. Triple therapy following the O'Dell scheme
was started for 13 patients (10.8 %). Mean non-
adherence proportions increase over time (Fig. 3). Non-
adherence proportions per DMARD also increased over
time, except for prednisone (Fig. 3). Non-adherence pro-
portions were highest for sulfasalazine. Methotrexate
was the most used DMARD, but for this drug, the non-
adherence proportion also increased to 0.3 after week
50. Using an 80 % adherence cutoff, for sulfasalazine the
least patients were adherent, declining from 80 %
(3 months) to 53.8 % (12 months). For MTX, adherence
declined from 91.2 % (3 months) to 69.3 % (12 months).
Over the study period, oral MTX was tapered the most.
Two patients used leflunomide, which was not depicted
in the graph.
T1: 3 months
Table 2 shows the univariate and multivariate regression
analyses for each time period. In the multivariate regres-
sion model for DAS28 outcome at 3 months, non-
adherence, weeks of treatment, baseline DAS28 and
baseline anxiety were entered as predictors. The influence
of non-adherence on disease activity is strongest in the
first months of treatment. At T1, being non-adherent
Fig. 1 Flow chart of respondents
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Table 1 Baseline characteristics
All patients Patients with complete follow-up Patients who became lost to follow-up
n = 120 n = 103 n = 17
Age (years), mean (SD) 55.7 (13.2) 55.6 (13) 56 (15.3)
Sex, female, number (%) 80 (66.7) 71 (68.9) 9 (52.9)
TJC, median (IQR) 5 (2–11) 4 (2–11) 6 (3–10)
SJC, median (IQR) 3 (2–7) 4 (2–8) 3 (1–7)
ESR, mean (SD) 30.5 (23.3) 30.9 (24.1) 27.7 (17.9)
DAS28, mean (SD) 4.66 (1.3) 4.66 (1.29) 4.6 (1.4)
HAQ, median (IQR) 0.75 (0.38–1.13) 0.75 (0.38–1.14) 0.75 (0.25–1)
RF, % positive 93 (77.5) 79 (76.7) 14 (82.4)
ACPA, % positive 85 (70.8) 75 (72.8) 10 (58.8)
Symptom duration, >6 wk (%) 104 (86.7) 91 (89.2) 13 (81.3)
Number of DMARDs at baseline (%) 1 54 (45) 52 44 (42.7) 10 (58.8)
2 39 (32.5) 34 (33) 5 (29.4)
3 23 (19.2) 21 (20.4) 2 (11.8)
4 4 (3.3) 4 (3.4) –
Subcutaneous use of MTX during 1-year follow-up (%) 20 (16.7) 16 (15.5) 4 (23.5)
Use of biologicals during 1-year follow-up (%) 11 (9.2) 10 (9.7) 1 (5.9)
Education level Low (%) 58 (50.4) 48 (48) 10 (66.7)
Intermediate (%) 34 (29.6) 29 (29) 5 (33.3)
High (%) 23 (20) 23 (23) –
HADS depression, mean (SD) 4.5 (SD 2.7) 4.4 (2.7) 4.6 (2.9)
HADS anxiety, mean (SD) 5.7 (SD 4.4) 5.9 (4.5) 4.5 (4.1)
SD standard deviation, TJC tender joint count, IQR interquartile range, SJC swollen joint count, ESR erythrocyte sedimentation rate, DAS28 28-joint count disease
activity score, HAQ health assessment questionnaire, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibodies, DMARDs disease-modifying antirheumatic
drugs, MTX methotrexate, HADS Hospital Anxiety and Depression Scale
month
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Fig. 2 Mean disease activity and percentage of patients in remission for patients more or less than 10 % adherent
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increases the DAS28 the most with 1.14 (95 % CI −0.07,
2.42), but is not significant with a p value of 0.08.
T1-T2: 3 to 6 months
In the time period 3 to 6 months, non-adherence, weeks
of treatment, baseline disease activity, standardized age
and baseline anxiety were entered in the multivariate
model. Non-adherence is a significant predictor of dis-
ease activity over time (independent of weeks of treat-
ment, and baseline disease activity). Biological use was
not taken into account in the multivariate model, since
only 1 patient used biologicals at that time.
T1-T2-T3: 3 to 9 months
For the time period 3 to 9 months, non-adherence, weeks
of treatment, baseline disease activity, standardized age,
and baseline anxiety were entered in the multivariate
model. Non-adherence was not a significant predictor of
disease activity in this time period adjusted for the other
variables.
T1-T2-T3-T4: 3 to 12 months
Over the whole first year of treatment, non-adherence
and the same variables as in the 3- to 9-month model
were entered in the multivariate model. Over this time
period, non-adherence was also not a significant pre-
dictor of disease activity adjusted for the other variables.
Other predictors
The number of weeks of treatment influences the
DAS28 at all time periods. The longer the time on treat-
ment, the lower the DAS28. The influence of time on
treatment is the highest at T1 (3 months) and decreases
when lengthening the time period.
The DAS28 score at the start of treatment is a pre-
dictor of the disease activity in the first year of treat-
ment. The effect of the baseline DAS28 on the DAS28
decreases over time, but remains a significant predictor
and lowers over time from 0.38 (T1) to 0.25 (T4).
Anxiety as measured with the HADS was multivariate
not a significant predictor of disease activity.
Discussion
The results of the present study indicate that non-
adherence is a serious problem in the treatment of RA
and that non-adherence corrected for other predictors
hampers achieving remission in the first 6 months of
treatment. Non-adherence increases over time for all
DMARDs, except for prednisone. It was a strong pre-
dictor of higher disease activity and thus contributes to
Fig. 3 Non-adherence over the 1-year follow-up period
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Table 2 Univariate and multivariate generalized linear mixed model for repeated data: determinants for DAS28 over the first year for rheumatoid arthritis patients over a 3-, 6-,
9- and 12-month period
T1: T1-2: T1-2-3: T1-2-3-4:
3 months 3–6 months 3-6-9 months 3–6–9–12 months
Univariate p value Multivariate p value Univariate p value Multivariate p value Univariate p value Multivariate p value Univariate p value Multivariate p value
Intercept 2.02 <0.01 1.45 <0.01 1.57 <0.01 1.65 <0.01
Non-adherence 1.22 0.06 1.14 0.08 1.18 0.01 1.04 0.03 0.71 0.07 0.52 0.18 0.28 0.40 0.19 0.57
Weeks on DMARDs −0.10 0.25 −0.08 0.10 −0.02 0.02 −0.02 <0.01 −0.02 <0.01 −0.02 <0.01 −0.01 <0.01 −0.01 <0.01
Baseline DAS28 0.36 <0.01 0.38 <0.01 0.35 <0.01 0.32 <0.01 0.32 <0.01 0.28 <0.01 0.30 <0.01 0.25 <0.01
Age (standardized) 0.01 0.17 0.001 0.92 0.02 0.07 0.01 0.29 0.02 0.03 0.01 0.11 0.02 0.03 0.01 0.11
Baseline anxiety 0.04 0.15 0.02 0.49 0.05 0.08 0.04 0.13 0.05 0.06 0.04 0.07 0.04 0.06 0.04 0.09
Education level −0.17 0.63 −0.16 0.27 −0.16 0.23 −0.16 0.20
Biological use # 1.73 0.02 # 0.09 0.83 −0.09 0.78
Subcutaneous MTX 0.38 0.51 0.43 0.23 0.32 0.24 0.16 0.51
Gender 0.22 0.39 0.19 0.44 0.14 0.53 0.08 0.72
Baseline depression 0.05 0.31 0.04 0.33 −0.03 0.43 0.02 0.62
ACPA/RF −0.11 0.40 −0.04 0.73 −0.04 0.74 −0.002 0.98
Number of DMARDs 0.08 0.54 0.03 0.79 0.02 0.83 −0.02 0.84
Symptom duration
>6 weeks
−0.07 0.84 0.04 0.92 0.05 0.88 0.03 0.92
DAS28 28-joint count disease activity score, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, ACPA anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor
#No/only one patient received biologicals at this time point
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failure in obtaining remission. In addition, weeks on
treatment and baseline disease activity influence the
disease activity over time in the first year of treatment.
The effect of non-adherence disappeared after T2. A
likely explanation for this effect is that if disease activity
remained too high, a step-up in therapy was made fol-
lowing the treat-to-target principle, regardless of un-
known underlying non-adherence behaviour [3]. Patients
are probably more likely to adhere to the next step-up in
treatment. An explanation for this is that they might
need time to get used to taking medication or might be
more adherent to more expensive and advanced therapy
[16]. Unfortunately, we could not measure adherence to
subcutaneous MTX and biological treatment, which was
given to respectively 19.4 and 7.8 % of patients, so we
could not confirm if this was in fact the case. The course
of the DAS28 over the first year of treatment in our co-
hort is similar to that of other studies in which patients
were treated according to the treat-to-target principle
[17], which supports our explanation that patients were
treated to target.
Time on treatment significantly influences the DAS28
at each time point. This is what we expect, because the
more time the patient is on treatment, the lower the
DAS28 is, especially in the early phase of treatment. The
effect of time on treatment is highest after 3 months,
and decreases during the course of the treatment. Dur-
ing the first months, time on treatment has larger effects
than later in the course of the treatment, because the
disease activity is then diminished.
Baseline disease activity is a significant predictor of the
DAS28, regardless of the time period the patient has
been treated. This is a known predictor of disease activ-
ity after 3 months [8], but no studies have been con-
ducted on the influence of baseline disease activity on
DAS28 after a longer period of time, except one study,
which showed that baseline disease activity was a signifi-
cant predictor of disease activity in established patients
after a 2-year period [10]. There is a tendency for the ef-
fect of baseline disease activity becoming less over time,
which is what we would expect when patients are
treated to target.
Interestingly, non-adherence increased over time, ex-
cept for prednisone. This is probably due to the immedi-
ate effect it has on the arthritis symptoms. For other
DMARDs, it can take up to several weeks for an effect
to be felt. It is logical that patients are more often non-
adherent to drugs that have a delayed effect on the
symptoms. For rheumatologists, it is important to be
aware that patients are more often adherent to prednis-
one than to other DMARDs.
Although all patients in this study were diagnosed with
RA according to the EULAR/ACR2010 criteria, there
was high variability in treatment strategies used. From
the data that we have, it is hard to determine if all
patients were indeed treated according to the treat-to-
target principles. Patients in this cohort might have been
subjected to over- or undertreatment, which might
increase or reduce the effects of non-adherence. Under-
treatment occurs when the patient does not receive a
step-up in treatment when needed according to the
DAS28. Research has shown that rheumatologists’ non-
adherence to the EULAR treatment guidelines in fact
results in not obtaining remission [18]. In the case of
undertreatment, being non-adherent will probably have
larger effects on the DAS28 score, whereas in the case of
overtreatment, the effect of non-adherence might be
smaller. To overcome this possibility of confounding, we
took in the regression analysis the number of DMARDs
prescribed at each time point into account. When a patient
has an increase in DAS28 and does not receive a step-up in
treatment with additional DMARDs, this patient could be
undertreated. In all the regression models, the number of
DMARDs was not a significant predictor of disease activity.
The effect of non-adherence still remained.
The outcomes of this study might have been subjected
to the ‘adherer effect’ [19]. Patients who adhere to the
rheumatologists’ prescription have better disease out-
comes, regardless of the underlying treatment. This theory
is based on the finding that behaviours of adherent people
are different from the behaviours of non-adherent people.
Adherent people have better global health outcomes, since
they have more healthy lifestyles, do not engage in risky
behaviours and are more adherent to non-pharmacologic
prescriptions [10, 20, 21]. If we take this limitation into ac-
count, we can conclude that we are dealing with a rather
adherent cohort. If more non-adherent patients had been
in the study, there would have been more variation in
adherence and maybe a stronger effect of non-adherence
on disease outcome.
A limitation of this study is that the effect of patient
education on adherence is unknown. Literature suggests
that poor education about the disease and its treatment
may have limited and short-term effects on non-
adherence [22]. In our study, all patients received at least
one education session from the specialized rheumatology
nurse, unless they were unwilling to receive such educa-
tion. However, the education given needs to be congru-
ent with the patients’ lay beliefs [22]. We do not know
whether this was the case. It may have been better if pa-
tient education was standardized over the participating
hospitals and measured in this cohort. Another limita-
tion is that there are a few missing DAS28 observations,
which we chose not to impute. Because of the explora-
tory character of this study no multiple testing correc-
tion is applied. This might have caused arbitrary
findings. However, if we had corrected for multiple test-
ing our selection criteria for the multivariable model
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would have been too stringent. A strength of our study
is that we measured adherence to DMARDs with the
most accurate method we have up to now: electronic
monitoring. Monitoring with MEMS might be seen as
an intervention, but this effect is regarded as negligible
[15]. Furthermore, patients can ‘cheat’ with MEMS, for
example by opening and closing the pill box but not tak-
ing the prescribed medication. Nonetheless, electronic
monitoring has been proven to be superior to patient self-
reports and pill count in measuring adherence [23, 24]. In
this study, electronic monitoring offered the advantage of
studying adherence over a continuum, allowing selection
of specific adherence period previous to DAS28 measure-
ment. This would not have been possible with the use
of questionnaires. Furthermore, using MEMS resulted
in adherence data on the separate DMARDs, which
would not have been possible if we had used conven-
tional questionnaires.
During the follow-up time of the cohort, 17 patients be-
came lost to follow-up. It could be that these patients are
less adherent than the patients that completed the follow-
up. We reviewed the patient files for information on the
disease activity from the patients that became lost to
follow-up. Strikingly, the disease activity from these patients
after 3 months was 0.54 points lower than for the patients
that stayed in the cohort, whereas the disease activity for
these patients after 1 year was 0.58 points higher than for
the patients who remained in the study. This finding sug-
gests that these patients reached low disease activity rela-
tively soon. Experiencing no or minimal symptom severity
might trigger these patients to become less adherent, be-
cause they do not experience the need for taking their
medication [16]. Non-adherence to their treatment might
have caused higher disease activity in a later stage.
Conclusions
This study showed that non-adherence is an important
predictor of higher disease activity in the first 6 months of
treatment. Since we know from the literature that it is im-
portant to reach remission as soon as possible to avoid per-
manent damage, the so-called window of opportunity, non-
adherence needs extra attention especially in the first year
of treatment. Rheumatologists should above all be aware
that non-adherence is an important factor to take into
account when treating the patient and evaluating DMARD
efficacy and side effects. Shared decision-making is seen as
an important overarching principle of care and was added
to the European League Against Rheumatism (EULAR)
recommendations for the management of rheumatoid arth-
ritis in 2010 [1]. Shared decision-making is indeed a way in
which the rheumatologist can improve patient adherence
[25–27]. In daily practice, the rheumatologist should build
towards an open and trustworthy relationship with the pa-
tient, in which non-adherence can be openly discussed.
When the rheumatologist has a trusting relation with the
patient, the rheumatologist will be able to know if non-
adherence is hampering the treatment goal.
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